Poloxamer 407 Hydrogels for Intravesical Instillation to Mouse Bladder: Gel-Forming Capacity and Retention Performance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상현 | - |
dc.contributor.author | 김성래 | - |
dc.contributor.author | 윤호엽 | - |
dc.contributor.author | 장인호 | - |
dc.contributor.author | 황영미 | - |
dc.contributor.author | 조민지 | - |
dc.contributor.author | 김명주 | - |
dc.contributor.author | 김수연 | - |
dc.contributor.author | 이상진 | - |
dc.contributor.author | 최영욱 | - |
dc.date.available | 2019-03-08T09:57:03Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1598-8341 | - |
dc.identifier.issn | 2233-5633 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/5101 | - |
dc.description.abstract | Purpose: Poloxamer 407 (P407) thermo-sensitive hydrogel formulations were developed to enhance the retention time in the urinary bladder after intravesical instillation. Materials and Methods: P407 hydrogels (P407Gels) containing 0.2 w/w% fluorescein isothiocyanate dextran (FD, MW 4 kDa) as a fluorescent probe were prepared by the cold method with different concentrations of the polymer (20, 25, and 30 w/w%). The gel-forming capacities were characterized in terms of gelation temperature (G-Temp), gelation time (G-Time), and gel duration (G-Dur). Homogenous dispersion of the probe throughout the hydrogel was observed by using fluorescence microscopy. The in vitro bladder simulation model was established to evaluate the retention and drug release properties. P407Gels in the solution state were administered to nude mice via urinary instillation, and the in vivo retention behavior of P407Gels was visualized by using an in vivo imaging system (IVIS). Results: P407Gels showed a thermo-reversible phase transition at 4°C (refrigerated; sol) and 37°C (body temperature; gel). The G-Temp, G-Time, and G-Dur of FD-free P407Gels were approximately 10°C–20°C, 12–30 seconds, and 12–35 hours, respectively, and were not altered by the addition of FD. Fluorescence imaging showed that FD was spread homogenously in the gelled P407 solution. In a bladder simulation model, even after repeated periodic filling-emptying cycles, the hydrogel formulation displayed excellent retention with continuous release of the probe over 8 hours. The FD release from P407Gels and the erosion of the gel, both of which followed zero-order kinetics, had a linear relationship (r2=0.988). IVIS demonstrated that the intravesical retention time of P407Gels was over 4 hours, which was longer than that of the FD solution (<1 hour), even though periodic urination occurred in the mice. Conclusions: FD release from P407Gels was erosion-controlled. P407Gels represent a promising system to enhance intravesical retention with extended drug delivery. | - |
dc.format.extent | 9 | - |
dc.publisher | 대한비뇨기종양학회 | - |
dc.title | Poloxamer 407 Hydrogels for Intravesical Instillation to Mouse Bladder: Gel-Forming Capacity and Retention Performance | - |
dc.type | Article | - |
dc.identifier.bibliographicCitation | 대한비뇨기종양학술지, v.15, no.3, pp 178 - 186 | - |
dc.identifier.kciid | ART002295323 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 186 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 178 | - |
dc.citation.title | 대한비뇨기종양학술지 | - |
dc.citation.volume | 15 | - |
dc.subject.keywordAuthor | Poloxamer 407 | - |
dc.subject.keywordAuthor | Intravesical delivery | - |
dc.subject.keywordAuthor | Thermo-sensitive hydrogel | - |
dc.subject.keywordAuthor | Bladder simulation model | - |
dc.subject.keywordAuthor | In vivo imaging system | - |
dc.description.journalRegisteredClass | kciCandi | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.